| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 4367 | 2018 |
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ... The lancet oncology 16 (4), 375-384, 2015 | 2953 | 2015 |
| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 2587 | 2015 |
| Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA MC Liu, GR Oxnard, EA Klein, C Swanton, MV Seiden, MC Liu, ... Annals of Oncology 31 (6), 745-759, 2020 | 964 | 2020 |
| Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration W Abida, A Patnaik, D Campbell, J Shapiro, AH Bryce, R McDermott, ... Journal of Clinical Oncology 38 (32), 3763-3772, 2020 | 556 | 2020 |
| Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types M Seiler, S Peng, AA Agrawal, J Palacino, T Teng, P Zhu, PG Smith, ... Cell reports 23 (1), 282-296. e4, 2018 | 379 | 2018 |
| Integrated molecular characterization of testicular germ cell tumors H Shen, J Shih, DP Hollern, L Wang, R Bowlby, SK Tickoo, V Thorsson, ... Cell reports 23 (11), 3392-3406, 2018 | 364 | 2018 |
| Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma MJ Borad, MD Champion, JB Egan, WS Liang, R Fonseca, AH Bryce, ... PLoS genetics 10 (2), e1004135, 2014 | 356 | 2014 |
| Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 … W Abida, D Campbell, A Patnaik, JD Shapiro, B Sautois, NJ Vogelzang, ... Clinical Cancer Research 26 (11), 2487-2496, 2020 | 338 | 2020 |
| Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome NJ Samadder, D Riegert-Johnson, L Boardman, D Rhodes, M Wick, ... JAMA oncology 7 (2), 230-237, 2021 | 201 | 2021 |
| CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD … ES Antonarakis, P Isaacsson Velho, W Fu, H Wang, N Agarwal, ... JCO precision oncology 4, 370-381, 2020 | 169 | 2020 |
| PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation RW Joseph, SZ Millis, EM Carballido, D Bryant, Z Gatalica, S Reddy, ... Cancer immunology research 3 (12), 1303-1307, 2015 | 163 | 2015 |
| Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome A Dispenzieri, MQ Lacy, SR Hayman, SK Kumar, F Buadi, D Dingli, ... European journal of haematology 80 (5), 397-406, 2008 | 150 | 2008 |
| NCCN guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 20 (12), 1288-1298, 2022 | 146 | 2022 |
| Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience TT DeLeon, MA Salomao, BA Aqel, MB Sonbol, RT Yokoda, AH Ali, ... Journal of gastrointestinal oncology 9 (6), 1054, 2018 | 141 | 2018 |
| Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations CH Marshall, AO Sokolova, AL McNatty, HH Cheng, MA Eisenberger, ... European urology 76 (4), 452-458, 2019 | 140 | 2019 |
| Rucaparib or physician’s choice in metastatic prostate cancer K Fizazi, JM Piulats, MN Reaume, P Ostler, R McDermott, JR Gingerich, ... New England Journal of Medicine 388 (8), 719-732, 2023 | 138 | 2023 |
| Evaluation of pre-analytical factors affecting plasma DNA analysis H Markus, T Contente-Cuomo, M Farooq, WS Liang, MJ Borad, ... Scientific reports 8 (1), 7375, 2018 | 127 | 2018 |
| Targeting TMPRSS2 in SARS-CoV-2 infection LB Baughn, N Sharma, E Elhaik, A Sekulic, AH Bryce, R Fonseca Mayo Clinic Proceedings 95 (9), 1989-1999, 2020 | 123 | 2020 |
| Translocation t (11; 14) and survival of patients with light chain (AL) amyloidosis AH Bryce, RP Ketterling, MA Gertz, M Lacy, RA Knudson, S Zeldenrust, ... haematologica 94 (3), 380, 2009 | 105 | 2009 |
